Intravenous immunoglobulin for severe infections: a survey of Canadian specialists

Journal of Critical Care
Kevin B LauplandChristopher J Doig

Abstract

To survey the opinions of Canadian critical care medicine and infectious disease specialists about the use of intravenous immunoglobulin (IVIG) for the treatment of severe infections. A scenario-based, cross-sectional survey of Canadian critical care medicine and infectious disease specialists was conducted from March to June 2003. The response rate was 291/487 (60%). Respondents were primarily medically trained and most (241/291; 83%) were practicing in large academic referral centers. Physicians reported that they would use IVIG in patients with streptococcal toxic shock syndrome (STSS; 218/288; 76%), streptococcal necrotizing fasciitis without STSS (143/286; 50%), staphylococcal toxic shock syndrome (75/288; 26%), streptococcal soft tissue infection without NF or STSS (31/286; 11%), and septic shock due to intra-abdominal focus (9/283; 3%). The majority (> or =67%) of respondents believed that it would be ethical to randomize patients to IVIG or placebo in a clinical trial in each of the five scenarios. One third (192/286) reported that it would not be ethical to randomize patients with STSS. Canadian specialists commonly report favoring the use of IVIG to treat STSS and necrotizing fasciitis but less commonly endorse this t...Continue Reading

References

Jul 23, 1992·The New England Journal of Medicine·UNKNOWN Intravenous Immunoglobulin Collaborative Study GroupMichel-Pierre Glauser
Jun 1, 1990·Science·P Marrack, J Kappler
Jan 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Lynn, J Cohen
Jul 24, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C A ZurawskiM M Farley
Sep 16, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·U E Nydegger, M Sturzenegger
May 29, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R KaulD E Low
Mar 10, 2001·The New England Journal of Medicine·G R BernardUNKNOWN Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group
Jan 24, 2002·Current Opinion in Critical Care·K Werdan
Apr 18, 2003·The New England Journal of Medicine·Greg S MartinMarc Moss
Jul 29, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jessica DarenbergUNKNOWN StreptIg Study Group

❮ Previous
Next ❯

Citations

Oct 29, 2009·Surgical Infections·Addison K MayUNKNOWN Surgical Infection Society
Nov 26, 2011·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·L Garrido-SánchezR Jodar-Masanes
Apr 21, 2009·Medicina clínica·Fernando Salgado OrdóñezUNKNOWN Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
Nov 4, 2009·Clinical and Experimental Immunology·H-P HartungS Jolles
Dec 7, 2006·Scandinavian Journal of Infectious Diseases·L ValiquetteA J McGeer

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
R KaulD E Low
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Jessica DarenbergStreptIg Study Group
© 2022 Meta ULC. All rights reserved